• 1
    Vaheri A, Henttonen H, Voutilainen L, Mustonen J, Sironen T, Vapalahti O. Hantavirus infections in Europe and their impact on public health. Rev Med Virol 2013; 23: 3549.
  • 2
    Vapalahti O, Mustonen J, Lundkvist Å, Henttonen H, Plyusnin A, Vaheri A. Hantavirus infections in Europe. Lancet Infect Dis 2003; 3: 65361.
  • 3
    Vaheri A, Strandin T, Hepojoki J et al. Uncovering the mysteries of hantavirus infections. Nat Rev Microbiol 2013; 11: 53950.
  • 4
    Clement J, Maes P, Lagrou K, Van Ranst M, Lameire N. A unifying hypothesis and a single name for a complex globally emerging infection: hantavirus disease. Eur J Clin Microbiol Infect Dis 2012; 31: 15.
  • 5
    Rasmuson J, Andersson C, Norrman E, Haney M, Evander M, Ahlm C. Time to revise the paradigm of hantavirus syndromes? Hantavirus pulmonary syndrome caused by European hantavirus. Eur J Clin Microbiol Infect Dis 2011; 30: 68590.
  • 6
    Heyman P, Vaheri A. Situation of hantavirus infections and haemorrhagic fever with renal syndrome in European countries as of December 2006. Euro Surveill 2008; 13: pii: 18925.
  • 7
    Makary P, Kanerva M, Ollgren J, Virtanen MJ, Vapalahti O, Lyytikäinen O. Disease burden of Puumala virus infections, 1995–2008. Epidemiol Infect 2010; 138: 148492.
  • 8
    Lähdevirta J. Nephropathia epidemica in Finland. A clinical histological and epidemiological study. Ann Clin Res 1971; 3: 154.
  • 9
    Mustonen J, Brummer-Korvenkontio M, Hedman K, Pasternack A, Pietilä K, Vaheri A. Nephropathia epidemica in Finland: a retrospective study of 126 cases. Scand J Infect Dis 1994; 26: 713.
  • 10
    Settergren B, Juto P, Trollfors B, Wadell G, Norrby SR. Clinical characteristics of nephropathia epidemica in Sweden: prospective study of 74 cases. Rev Infect Dis 1989; 11: 9217.
  • 11
    Braun N, Haap M, Overkamp D et al. Characterization and outcome following Puumala virus infection: a retrospective analysis of 75 cases. Nephrol Dial Transplant 2010; 25: 29973003.
  • 12
    Mustonen J, Helin H, Pietilä K et al. Renal biopsy findings and clinicopathologic correlations in nephropathia epidemica. Clin Nephrol 1994; 41: 1216.
  • 13
    Temonen M, Mustonen J, Helin H, Pasternack A, Vaheri A, Holthöfer H. Cytokines, adhesion molecules, and cellular infiltration in nephropathia epidemica kidneys: an immunohistochemical study. Clin Immunol Immunopathol 1996; 78: 4755.
  • 14
    Mustonen J, Partanen J, Kanerva M et al. Genetic susceptibility to severe course of nephropathia epidemica caused by Puumala hantavirus. Kidney Int 1996; 49: 21721.
  • 15
    Mäkelä S, Mustonen J, Ala-Houhala I et al. Human leukocyte antigen-B8-DR3 is a more important risk factor for severe Puumala hantavirus infection than the tumor necrosis factor-alpha(-308) G/A polymorphism. J Infect Dis 2002; 186: 8436.
  • 16
    Gavrilovskaya IN, Shepley M, Shaw R, Ginsberg MH, Mackow ER. beta3 Integrins mediate the cellular entry of hantaviruses that cause respiratory failure. Proc Natl Acad Sci USA 1998; 95: 70749.
  • 17
    Gavrilovskaya IN, Brown EJ, Ginsberg MH, Mackow ER. Cellular entry of hantaviruses which cause hemorrhagic fever with renal syndrome is mediated by beta3 integrins. J Virol 1999; 73: 39519.
  • 18
    Zaki SR, Greer PW, Coffield LM et al. Hantavirus pulmonary syndrome. Pathogenesis of an emerging infectious disease. Am J Pathol 1995; 146: 55279.
  • 19
    Cosgriff TM. Mechanisms of disease in Hantavirus infection: pathophysiology of hemorrhagic fever with renal syndrome. Rev Infect Dis 1991; 13: 97107.
  • 20
    Kanerva M, Mustonen J, Vaheri A. Pathogenesis of Puumala and other hantavirus infections. Rev Med Virol 1998; 8: 6786.
  • 21
    Ossowski L, Aguirre-Ghiso JA. Urokinase receptor and integrin partnership: coordination of signaling for cell adhesion, migration and growth. Curr Opin Cell Biol 2000; 12: 61320.
  • 22
    Thuno M, Macho B, Eugen-Olsen J. suPAR: the molecular crystal ball. Dis Markers 2009; 27: 15772.
  • 23
    Florquin S, van den Berg JG, Olszyna DP et al. Release of urokinase plasminogen activator receptor during urosepsis and endotoxemia. Kidney Int 2001; 59: 205461.
  • 24
    Roelofs JJ, Rowshani AT, van den Berg JG et al. Expression of urokinase plasminogen activator and its receptor during acute renal allograft rejection. Kidney Int 2003; 64: 184553.
  • 25
    Eugen-Olsen J, Gustafson P, Sidenius N et al. The serum level of soluble urokinase receptor is elevated in tuberculosis patients and predicts mortality during treatment: a community study from Guinea-Bissau. Int J Tuberc Lung Dis 2002; 6: 68692.
  • 26
    Huttunen R, Syrjänen J, Vuento R et al. Plasma level of soluble urokinase-type plasminogen activator receptor as a predictor of disease severity and case fatality in patients with bacteraemia: a prospective cohort study. J Intern Med 2011; 270: 3240.
  • 27
    Koch A, Voigt S, Kruschinski C et al. Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients. Crit Care 2011; 15: R63.
  • 28
    Mölkänen T, Ruotsalainen E, Thorball CW, Järvinen A. Elevated soluble urokinase plasminogen activator receptor (suPAR) predicts mortality in Staphylococcus aureus bacteremia. Eur J Clin Microbiol Infect Dis 2011; 30: 141724.
  • 29
    Sidenius N, Sier CF, Ullum H et al. Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection. Blood 2000; 96: 40915.
  • 30
    Ostrowski SR, Ullum H, Goka BQ et al. Plasma concentrations of soluble urokinase-type plasminogen activator receptor are increased in patients with malaria and are associated with a poor clinical or a fatal outcome. J Infect Dis 2005; 191: 133141.
  • 31
    Uusitalo-Seppälä R, Huttunen R, Tarkka M et al. Soluble urokinase-type plasminogen activator receptor in patients with suspected infection in the emergency room: a prospective cohort study. J Intern Med 2012; 272: 24756.
  • 32
    Eugen-Olsen J, Andersen O, Linneberg A et al. Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population. J Intern Med 2010; 268: 296308.
  • 33
    Wei C, Trachtman H, Li J et al. Circulating suPAR in two cohorts of primary FSGS. J Am Soc Nephrol 2012; 23: 20519.
  • 34
    Wei C, El Hindi S, Li J et al. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med 2011; 17: 95260.
  • 35
    Sier CF, Sidenius N, Mariani A et al. Presence of urokinase-type plasminogen activator receptor in urine of cancer patients and its possible clinical relevance. Lab Invest 1999; 79: 71722.
  • 36
    Mustjoki S, Sidenius N, Sier CF et al. Soluble urokinase receptor levels correlate with number of circulating tumor cells in acute myeloid leukemia and decrease rapidly during chemotherapy. Cancer Res 2000; 60: 712632.
  • 37
    Rabna P, Andersen A, Wejse C et al. Urine suPAR levels compared with plasma suPAR levels as predictors of post-consultation mortality risk among individuals assumed to be TB-negative: a prospective cohort study. Inflammation 2010; 33: 37480.
  • 38
    Sorio C, Mafficini A, Furlan F et al. Elevated urinary levels of urokinase-type plasminogen activator receptor (uPAR) in pancreatic ductal adenocarcinoma identify a clinically high-risk group. BMC Cancer 2011; 11: 448.
  • 39
    Outinen TK, Tervo L, Mäkelä S et al. Plasma levels of soluble urokinase-type plasminogen activator receptor associate with the clinical severity of acute Puumala hantavirus infection. PLoS ONE 2013; 8: e71335.
  • 40
    Vapalahti O, Lundkvist Å, Kallio-Kokko H et al. Antigenic properties and diagnostic potential of Puumala virus nucleocapsid protein expressed in insect cells. J Clin Microbiol 1996; 34: 11925.
  • 41
    Outinen TK, Mäkelä SM, Ala-Houhala IO et al. High activity of indoleamine 2,3-dioxygenase is associated with renal insufficiency in Puumala hantavirus induced nephropathia epidemica. J Med Virol 2011; 83: 7317.
  • 42
    Libraty DH, Mäkelä S, Vlk J et al. The degree of leukocytosis and urine GATA-3 mRNA levels are risk factors for severe acute kidney injury in Puumala virus nephropathia epidemica. PLoS ONE 2012; 7: e35402.
  • 43
    Schrocksnadel K, Wirleitner B, Winkler C, Fuchs D. Monitoring tryptophan metabolism in chronic immune activation. Clin Chim Acta 2006; 364: 8290.
  • 44
    Laich A, Neurauter G, Widner B, Fuchs D. More rapid method for simultaneous measurement of tryptophan and kynurenine by HPLC. Clin Chem 2002; 48: 57981.
  • 45
    McQuarrie EP, Shakerdi L, Jardine AG, Fox JG, Mackinnon B. Fractional excretions of albumin and IgG are the best predictors of progression in primary glomerulonephritis. Nephrol Dial Transplant 2011; 26: 15639.
  • 46
    Mäkelä S, Mustonen J, Ala-Houhala I et al. Urinary excretion of interleukin-6 correlates with proteinuria in acute Puumala hantavirus-induced nephritis. Am J Kidney Dis 2004; 43: 80916.
  • 47
    Ecke TH, Schlechte HH, Schulze G, Lenk SV, Loening SA. Four tumour markers for urinary bladder cancer–tissue polypeptide antigen (TPA), HER-2/neu (ERB B2), urokinase-type plasminogen activator receptor (uPAR) and TP53 mutation. Anticancer Res 2005; 25: 63541.
  • 48
    Soydinc HO, Duranyildiz D, Guney N, Derin D, Yasasever V. Utility of serum and urine uPAR levels for diagnosis of breast cancer. Asian Pac J Cancer Prev 2012; 13: 28879.
  • 49
    Sier CF, Nicoletti I, Santovito ML et al. Metabolism of tumour-derived urokinase receptor and receptor fragments in cancer patients and xenografted mice. Thromb Haemost 2004; 91: 40311.
  • 50
    Andersen O, Eugen-Olsen J, Kofoed K, Iversen J, Haugaard SB. Soluble urokinase plasminogen activator receptor is a marker of dysmetabolism in HIV-infected patients receiving highly active antiretroviral therapy. J Med Virol 2008; 80: 20916.
  • 51
    Sidenius N, Sier CF, Blasi F. Shedding and cleavage of the urokinase receptor (uPAR): identification and characterisation of uPAR fragments in vitro and in vivo. FEBS Lett 2000; 475: 526.
  • 52
    Wagner SN, Atkinson MJ, Wagner C, Hofler H, Schmitt M, Wilhelm O. Sites of urokinase-type plasminogen activator expression and distribution of its receptor in the normal human kidney. Histochem Cell Biol 1996; 105: 5360.
  • 53
    Jefferson JA, Alpers CE. Glomerular disease: ‘suPAR’-exciting times for FSGS. Nat Rev Nephrol 2013; 9: 1278.
  • 54
    Shankland SJ, Pollak MR. A suPAR circulating factor causes kidney disease. Nat Med 2011; 17: 9267.
  • 55
    Franco Palacios CR, Lieske JC, Wadei HM et al. Urine but not serum soluble urokinase receptor (suPAR) may identify cases of recurrent FSGS in kidney transplant candidates. Transplantation 2013; 96: 3949.
  • 56
    Krautkramer E, Grouls S, Stein N, Reiser J, Zeier M. Pathogenic old world hantaviruses infect renal glomerular and tubular cells and induce disassembling of cell-to-cell contacts. J Virol 2011; 85: 981123.
  • 57
    Li XD, Kukkonen S, Vapalahti O, Plyusnin A, Lankinen H, Vaheri A. Tula hantavirus infection of Vero E6 cells induces apoptosis involving caspase 8 activation. J Gen Virol 2004; 85: 32618.
  • 58
    Markotic A, Hensley L, Geisbert T, Spik K, Schmaljohn C. Hantaviruses induce cytopathic effects and apoptosis in continuous human embryonic kidney cells. J Gen Virol 2003; 84: 2197202.
  • 59
    Collan Y, Mihatsch MJ, Lähdevirta J, Jokinen EJ, Romppanen T, Jantunen E. Nephropathia epidemica: mild variant of hemorrhagic fever with renal syndrome. Kidney Int Suppl 1991; 35: S6271.
  • 60
    Collan Y, Lähdevirta J, Jokinen EJ. Electron microscopy of nephropathia epidemica. Glomerular changes. Virchows Arch A Pathol Anat Histol 1978; 377: 12944.